Gardasil Vaccine Now Promoted To 12-Year Old Boys For Mouth and Throat Cancers To Double The Market
What's the best way to attract new patients for a vaccine heavily marketed to only girls? Why open up the market to boys of course. The HPV vaccine is possibly the biggest vaccine hoax in the last century being nothing more than a worldwide exercise in profiteering at the expense of children's health. Another massively flawed study (basically routine for the HPV vaccine) will give Gardasil manufacturer, Merck & Co., the green light to once again create a vaccine awareness campaign on the pretext that it prevents mouth and throat cancers.
There are truthfully no safe vaccines, however the HPV vaccine is one of the 5 vaccines I strongly recommend to avoid. It is perhaps the one vaccine based on the most misrepresented data and unproven assumptions.
In 2011, the Annals of Medicine exposed the fraudulent nature of Human papillomavirus (HPV) vaccines such as Gardasil and Cervarix. Key messages the researchers reported include a lack of evidence for any HPV vaccines in preventing cervical cancer and lack of evaluation of health risks.
New Market Targeting 12-year old Boys
A new study indicates suggests that vaccinating 12-year-old boys against the humanpapilloma virus (HPV) will prevent oropharyngeal squamous cell cancer, a cancer that starts at the back of the throat and mouth, and involves the tonsils and base of the tongue.
"Gradually bit by bit, perhaps, people are thinking that it is a good thing to do. Because there's no reason why we shouldn't protect the men also," says Dr. Lillian Siu, a medical oncologist at Toronto's Princess Margaret Cancer Center. Siu is one of the senior authors of the study.
But a senior vaccine researcher questions the finding, saying the study design chosen wasn't the right one for testing this kind of question. The authors admit the mathematical model they used did not take into account other variables which may have influenced the out come of the study.
the CDC's Advisory Committee on Immunization Practices (ACIP) recommended routine HPV vaccination for males aged 11 to 12 years and catch-up vaccination for males aged 13 to 21 which is another popular market vaccine manufacturers are targeting.
ACIP is a group of individuals hand-picked by members of the CDC, that recommends which vaccines are administered to American children. Working mainly in secret, ACIP members frequently have financial links to vaccine manufacturers. Dependent on federal CDC funding, administrators of state vaccination programs follow CDC directives by influencing state legislators to mandate new vaccines. Federal vaccine funds can be denied to states that do not "vigorously enforce" mandatory vaccination laws.
The false belief is that as the number of girls and women who are vaccinated against HPV rises, fewer of these viruses will circulate so many males will get indirect protection.
"When you've got 50 per cent uptake (in girls), it makes more sense to immunize the boys because then you increase your chances of getting herd immunity," says Dr. Natasha Crowcroft from Public Health Ontario who was not involved in this study.
False Data and Junk Science
Gardasil's manufacturer, Merck, states on their website that Gardasil does more than help prevent cervical cancer, it protects against other HPV diseases, too. Merck further claims that Gardasil does not prevent all types of cervical cancer. Similarly, the CDC and the FDA claim that the Gardasil vaccine is an important cervical cancer prevention tool that will potentially benefit the health of millions of women and based on all of the information we have today, CDC recommends HPV vaccination for the prevention of most types of cervical cancer. All four of these statements are false and at significant variance with the available evidence as they imply that Gardasil can indeed protect against some types of cervical cancer which has never been proven.
At present there are no significant data showing that either Gardasil or Cervarix (GlaxoSmithKline) can prevent any type of cervical cancer since the testing period employed was too short to evaluate long-term benefits of HPV vaccination. The longest follow-up data from phase II trials for Gardasil and Cervarix are 5 and 8.4 years, respectively, while invasive cervical cancer takes up to 20 -40 years to develop from the time of acquisition of HPV infection.
As adverse side effects from the new vaccine continue to mount, the opposition to the vaccine has grown. A lead researcher, Diane Harper, a scientist and physician who has spent 20 years developing the vaccine for human papillomavirus, says the HPV vaccine is not for younger girls, and that it is "silly" for states to be mandating them.
Here are just a few of the potential side effects caused by the HPV vaccine:
convulsions [which are serious reactions with risks of serious brain injury];
grand mal seizures and convulsions;
blood problems, leading to unexplained bruising or bleeding
Due to hundreds of adverse reactions to cervical cancer vaccine reported in Japan, teenagers were injured and disabled by Cervarix and Gardasil HPV vaccination campaigns are now continue to voice their disdain with efforts to permanently end the government’s subsidy program for the toxic injections. In July 2013, their health ministry issued a nationwide notice that cervical cancer vaccinations should no longer be recommended. Japanese teens who received the vaccines were confined to wheelchairs with damage to their brains and spinal cord.
A class-action lawsuit has been filed in Australia against drug maker Merck by a young woman who suffered autoimmune and neurological health problems following injections with the HPV vaccine, Gardasil
Between May 2009 and September 2010, 16 deaths occurred after Gardasil vaccination, along with 789 reports of "serious" adverse reactions; 213 cases of permanent disability; and 25 cases of Guillain Barre Syndrome. Between September 1, 2010 and September 15, 2011, yet another 26 deaths were reported.
Consider some of the facts related to cervical cancer and the HPV vaccine:
Cervical cancer is not a major health issue for women under good gynecological care.
HPV vaccines may protect against four strains of high-risk HPV but the duration of effectiveness is not clear; best estimates to date are from 4 to 6 years
HPV vaccination does not eliminate the need for traditional cervical cancer screening
Prior exposure to vaccine-relevant strains of HPV can increase the risk of cancer by 44.6% if injected with Gardasil and 32.5% if injected with Cervarix
HPV is not transmitted solely via sexual contact, there are multiple other ways to have been exposed
There are already well over 300 reports to VAERS of abnormal pap smears post-vaccination
HPV does not cause cervical cancer, it is the persistant infection, not the virus, that determines the risk
93% of women initially infected with a particular strain of HPV will not show the same strain four menstrual cycles later
Most cervical cancer deaths in the United States, and developed countries, are people who are not under regular OB/GYN care.
The National Cancer Institute has no data on which HPV genotypes are prevalent in the United States.
A CDC study showed that HPV types 16 and 18, the two HPV vaccine-relevant strains, are NOT the prevalent types in American women.
Three published papers on HPV prevalence in the U.S., indicated that types 62, 84 and 52 are the most prevalent. None of these are targeted in either approved HPV vaccine, and type 52 is an accepted high-risk "carcinogenic" strain of HPV.
If a person has prior exposure to vaccine-relevant HPV prior to injection, the vaccine provides no benefit, but does provide potential risks.
If a woman is infected with HPV-16 in January, HPV-18 in July, and HPV-31 in December, her cancer risk is zero. Even though these are all high risk types, they are considered transient. It takes repeated infection by the same type to perhaps pose a risk of cervical cancer.
Even when a woman has persistant infection by the same type, if her lifestyle is healthy (she does not smoke, does not take oral contraceptives, does not have multiple sexual partners, does not have a compromised immune system) her risk of cervical cancer is still minimal.
HPV is not necessarily a sexually transmittable virus--you can get it other ways.
American women currently spend $10 billion on unnecessary colposcopies (cervical biopsies) every year, primarily because the currently used HPV tests frequently display false positive results.
A study conducted by Harvard School of Public Health estimated that 95% of cervical biopsies in the United States are not necessary.
If a young woman is considering taking an HPV vaccine, it is critical that she know if she has been exposed to HPV, and if so, what genotype.
Nothing has been proven to be more effective at controlling cervical cancer than pap smear technology.
To date, the efficacy of HPV vaccines in preventing cervical cancer has not been demonstrated, while vaccine risks remain to be fully evaluated.
Current worldwide HPV vaccination practices with either of the two HPV vaccines appear to be neither justified by long-term health benefits nor economically viable, nor is there any evidence that HPV vaccination (even if proven effective against cervical cancer) would reduce the rate of cervical cancer beyond what Pap screening has already achieved.
Cumulatively, the list of serious adverse reactions related to HPV vaccination worldwide includes cervical cancer itself.
The almost exclusive reliance on manufacturers sponsored studies, often of questionable quality, as a base for vaccine policy-making should be discontinued.
the presentation of partial and non-factual information regarding cervical cancer risks and the usefulness of HPV vaccines, as cited above, is neither scientific nor ethical.
Decline Continues In HPV Vaccine Completion Rate Thanks To Informed Parents
Thanks to the wealth of information available on the HPV vaccine fraud, the proportion of insured girls and young women completing the human papillomavirus (HPV) vaccine among those who initiated the series has dropped significantly -- as much as 63 percent -- since the vaccine was approved in 2006, according to new research from the University of Texas Medical Branch (UTMB) in Galveston.
This is the primary reason and attempt to increase the market demographic to young boys.
Of those surveyed by Planned Parenthood, only about a third (30.7 percent) of parents had elected to have their children vaccinated. An additional 4.8 percent had children who had received two out of the three necessary doses, while another 6.7 percent had only one of the three necessary doses. Over 40 percent of parents polled were either undecided about whether their child should receive the vaccine or had decided not to vaccinate their child against HPV.
A study published in Cancer, revealed the steepest decline in vaccine completion among girls and young women aged nine to 18 -- the age group according to medical officials that should receive the vaccine in three doses over six months -- a message that has been drilled into parents for just over five years. It's a sign that parents are listening and completing their own research on the dangers of HPV vaccination despite Doctor's recommendations.